‘Life-changing' Sydney-based clinic is transforming the skin of thousands of shoppers with common skin concerns
Seasonal change can cause havoc on our skin, increasing dryness, irritation, sensitivity, and even acne.
While switching up a skincare routine can help boost your skin barrier, seeking a long-term solution is going to be your best bet for keeping a complexion looking happy and healthy.
That's why hundreds of shoppers are rushing to book an appointment at renowned Sydney-based skin clinic, SDL (Sydney Dermal Lounge).
With three salons across the city, SDL is 'leading the bare skin movement,' providing a wide range of effective skin treatments that can help to improve the appearance of many common skin concerns.
Because let's face it; a difficult skin journey can leave you feeling exhausted, overwhelmed, and low on confidence.
Whether you're battling acne, redness, a dry or irritated complexion, SDL founder Savannah Lee made it her mission to create a clinic that offers effective, medical-grade solutions.
'I opened my first clinic when I was 26, with an 18-month-old on my hip and a vision that felt so much bigger than me,' Savannah tells Best Picks.
'At the time, everyone was opening laser hair removal clinics. It was the safe bet. The easy sell. But I wasn't interested in shortcuts or trends. I had already spent over a decade in the industry managing some of Australia's leading laser and cosmetic clinics and I had seen the gaps up close.'
Instead, SDL provides a range of 'life-changing' treatments across skin health, skin correction, maintenance and hair restoration for 'real results'.
Combined with expert-lead guidance from a team who have gone through their own skin struggles, the Sydney-based clinic ensures that each and every shopper leaves feeling comfortable and confident with their skin.
Offering more than just a 'quick fix,' SDL is home to many popular treatments including HydraFacial and AviClear laser.
Savannah says that 'if something doesn't deliver results — we don't offer it. We're known for skin correction that works.'
If you're ready to kickstart your skincare journey, SDL offers an in-depth 60 minute skin consultation to discuss any skin concerns and indentify which result-driven products and treatments are best suited.
'I wanted to focus on skin. Not just treating it. But correcting it properly and with full certainty,' she adds.
With nearly 80,000 followers on Instagram and dozens of in credible before and after shots, it's no surprise that shoppers are rushing to book an appointment.
SDL is one of the few clinics in Sydney to offer AviClear, a laser treatment for treating acne.
It has minimal downtime with 30-minute sessions, done in series of three, spaced four to six weeks apart.
'It's not just about clearing skin — it's about doing it safely and long-term.'
'We see so many clients who've been through harsh medications, antibiotics, and even multiple rounds of Accutane — only for the acne to return. And the side effects? Gut issues. Mood swings. Hormonal imbalance.'
'The full course is around $3,000 — and while that might sound like a big number up front, it's often less than what people spend over the years trying to control acne through skincare, prescriptions, supplements, and coverups.'
Shoppers who have visited SDL have given the clinic rave reviews.
'The ladies at Sydney Dermal Lounge are so friendly and professional. They always make me feel gorgeous and relaxed after my treatments. Love their work and totally recommend,' one shopper commented.
'THIS IS THE PLACE TO VISIT! I am a mature aged person and I visit for ant-aging laser skin tightening and I undergo pigmentation treatment. I feel and look 20 years younger,' another wrote.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Age
10 hours ago
- The Age
Ozempic in a pill? The next generation of weight-loss drugs emerges
'The development of GLP-1 and incretin-based drugs has revolutionised the space. It has carved out the biggest class of drugs ever. And it has the power to truly revolutionise our health-span,' said Associate Professor Garron Dodd, head of the Metabolic Neuroscience Research Laboratory at the University of Melbourne and founder of Gallant Bio, which is developing its own obesity drugs. 'It's a glorious dawn, but it's just the start.' Weight loss in a pill Much as our eyes and ears sense the world and send data to our brains, our digestive tracts need ways of sending back data on what they are eating, and how much. They do this, in part, by secreting various chemical signals – hormones. Glucagon-like peptide-1 is secreted by the intestines and triggers the pancreas to produce insulin. The first GLP-1 drugs took advantage of this to become powerful treatments for diabetes. But GLP-1 has much wider effects beyond blood-sugar control. Receptors for the hormone spread throughout the body, even in the brain, where they trigger a feeling of fullness and decrease appetite. A once-weekly dose of semaglutide, plus lifestyle changes, led volunteers in a phase 3 trial to lose 14.9 per cent of their body weight over 15 months. GLP-1 drugs like Wegovy essentially copy that human hormone. That makes them fragile. They need to be kept refrigerated, and injected subcutaneously rather than taken by mouth – as the stomach's acid would quickly break them down. An oral version of semaglutide has been developed, but only 1 per cent of the drug actually makes its way to the target receptors, and it appears less effective than the injectable version for weight loss. Loading Researchers at Japan's Chugai Pharmaceutical Co figured out a way around this problem. They designed a small molecule that can bind to the same receptor as GLP-1 and trigger it. It mimics the effect without mimicking the structure. 'It's a development I never would have thought feasible,' said Professor Michael Horowitz, a University of Adelaide researcher who authored a commentary on the drug in the Lancet. Chugai licensed the molecule to US-based Eli Lilly in 2018. Last week, the company reported participants on the highest dose in a clinical trial lost 7.9 per cent of their body weight over 40 weeks. The full details of the trial have not yet been reported, and whether the weight loss is maintained over the longer term is unclear. More than a quarter of patients reported diarrhoea, 16 per cent nausea and 14 per cent vomiting. The preliminary results are 'close enough to broadly call it similar' to semaglutide, said Professor Jonathan Shaw, who led the Australian arm of Lilly's trial at the Baker Heart and Diabetes Institute in Melbourne. 'I don't think we can confidently say it's better or worse. It's definitely in the same ballpark.' It's also not known if the drug will offer the range of other benefits that GLP-1 inhibitors provide in addition to weight loss, like reductions in cardiovascular disease and Alzheimer's risk (and maybe even addictive behaviours). Horowitz said the efficacy data was promising, but he wanted to see more information about adverse effects, which he said were understated generally across semaglutide trials because they relied on patients to report their own side effects. 'It hasn't served the interests of pharma to quantify how well this is tolerated.' Pfizer was developing a similar once-daily GLP-1 pill but cancelled the program in April after a patient in a clinical trial suffered liver damage. A pill should, theoretically, be cheaper and easier to make than an injector – Novo Nordisk, maker of Wegovy and its diabetes drug antecedent Ozempic, has struggled to keep up with demand for semaglutide – and dramatically easier to transport. At present, the drug must be kept refrigerated right from European factories to a patient's home. 'That all adds to the cost,' said Shaw. There could also be cost benefits from increased competition as more drugs are approved – possibly pushing the price down far enough for governments to consider subsidising it. Lilly expects to apply for regulatory approval for the drug later this year. While orforglipron has attracted the most excitement – Eli Lilly's shares have surged since they announced the trial results – it is just one of several new drugs in late-stage development. These drugs might be of particular value to 15 per cent or so of people whose bodies do not seem to respond to semaglutide. And people don't seem to stay on the injectable drugs – less than half are still using them a year later, per a study 2024 study – despite the fact weight rebound is likely if you stop using them. 'Is it the injection? Is it the cost? Or is it due to adverse effects? We don't know,' said Horowitz. The new drugs might also offer weight-loss benefits. Mounjaro, for example, mimics both GLP-1 and the gastric inhibitory polypeptide, which increases metabolism and appears to lead to better weight-loss results. The new drugs, like Lilly's retatrutide, target even more receptors, with the hope of even greater effects. It's all good news for Rochelle McDonald. She does not mind taking a weekly injection – 'the stabby-stab' – now she's found ways of coping with the side effects. But paying $240 a month for her current dose of the medicine is 'a commitment in itself'. 'I think a daily pill would be good,' she said. 'If it comes in at a good price point.'
Sydney Morning Herald
10 hours ago
- Sydney Morning Herald
Ozempic in a pill? The next generation of weight-loss drugs emerges
'The development of GLP-1 and incretin-based drugs has revolutionised the space. It has carved out the biggest class of drugs ever. And it has the power to truly revolutionise our health-span,' said Associate Professor Garron Dodd, head of the Metabolic Neuroscience Research Laboratory at the University of Melbourne and founder of Gallant Bio, which is developing its own obesity drugs. 'It's a glorious dawn, but it's just the start.' Weight loss in a pill Much as our eyes and ears sense the world and send data to our brains, our digestive tracts need ways of sending back data on what they are eating, and how much. They do this, in part, by secreting various chemical signals – hormones. Glucagon-like peptide-1 is secreted by the intestines and triggers the pancreas to produce insulin. The first GLP-1 drugs took advantage of this to become powerful treatments for diabetes. But GLP-1 has much wider effects beyond blood-sugar control. Receptors for the hormone spread throughout the body, even in the brain, where they trigger a feeling of fullness and decrease appetite. A once-weekly dose of semaglutide, plus lifestyle changes, led volunteers in a phase 3 trial to lose 14.9 per cent of their body weight over 15 months. GLP-1 drugs like Wegovy essentially copy that human hormone. That makes them fragile. They need to be kept refrigerated, and injected subcutaneously rather than taken by mouth – as the stomach's acid would quickly break them down. An oral version of semaglutide has been developed, but only 1 per cent of the drug actually makes its way to the target receptors, and it appears less effective than the injectable version for weight loss. Loading Researchers at Japan's Chugai Pharmaceutical Co figured out a way around this problem. They designed a small molecule that can bind to the same receptor as GLP-1 and trigger it. It mimics the effect without mimicking the structure. 'It's a development I never would have thought feasible,' said Professor Michael Horowitz, a University of Adelaide researcher who authored a commentary on the drug in the Lancet. Chugai licensed the molecule to US-based Eli Lilly in 2018. Last week, the company reported participants on the highest dose in a clinical trial lost 7.9 per cent of their body weight over 40 weeks. The full details of the trial have not yet been reported, and whether the weight loss is maintained over the longer term is unclear. More than a quarter of patients reported diarrhoea, 16 per cent nausea and 14 per cent vomiting. The preliminary results are 'close enough to broadly call it similar' to semaglutide, said Professor Jonathan Shaw, who led the Australian arm of Lilly's trial at the Baker Heart and Diabetes Institute in Melbourne. 'I don't think we can confidently say it's better or worse. It's definitely in the same ballpark.' It's also not known if the drug will offer the range of other benefits that GLP-1 inhibitors provide in addition to weight loss, like reductions in cardiovascular disease and Alzheimer's risk (and maybe even addictive behaviours). Horowitz said the efficacy data was promising, but he wanted to see more information about adverse effects, which he said were understated generally across semaglutide trials because they relied on patients to report their own side effects. 'It hasn't served the interests of pharma to quantify how well this is tolerated.' Pfizer was developing a similar once-daily GLP-1 pill but cancelled the program in April after a patient in a clinical trial suffered liver damage. A pill should, theoretically, be cheaper and easier to make than an injector – Novo Nordisk, maker of Wegovy and its diabetes drug antecedent Ozempic, has struggled to keep up with demand for semaglutide – and dramatically easier to transport. At present, the drug must be kept refrigerated right from European factories to a patient's home. 'That all adds to the cost,' said Shaw. There could also be cost benefits from increased competition as more drugs are approved – possibly pushing the price down far enough for governments to consider subsidising it. Lilly expects to apply for regulatory approval for the drug later this year. While orforglipron has attracted the most excitement – Eli Lilly's shares have surged since they announced the trial results – it is just one of several new drugs in late-stage development. These drugs might be of particular value to 15 per cent or so of people whose bodies do not seem to respond to semaglutide. And people don't seem to stay on the injectable drugs – less than half are still using them a year later, per a study 2024 study – despite the fact weight rebound is likely if you stop using them. 'Is it the injection? Is it the cost? Or is it due to adverse effects? We don't know,' said Horowitz. The new drugs might also offer weight-loss benefits. Mounjaro, for example, mimics both GLP-1 and the gastric inhibitory polypeptide, which increases metabolism and appears to lead to better weight-loss results. The new drugs, like Lilly's retatrutide, target even more receptors, with the hope of even greater effects. It's all good news for Rochelle McDonald. She does not mind taking a weekly injection – 'the stabby-stab' – now she's found ways of coping with the side effects. But paying $240 a month for her current dose of the medicine is 'a commitment in itself'. 'I think a daily pill would be good,' she said. 'If it comes in at a good price point.'
News.com.au
11 hours ago
- News.com.au
Here's what you're really inhaling in vapes
Welcome to Ask Doctor Zac, a weekly column from This week, Dr Zac Turner explores the truth about vaping. QUESTION: Hey Dr Zac, I've heard that some of the vapes coming into Sydney now have synthetic fentanyl added to make them more addictive. These are the ones from China and they're illegal. Is this just BS made up by the government to force us to buy vapes from the doctor — or is there any truth to it? – Rory, 23, Nowra, NSW ANSWER: Hi Rory, This might sound like a wild rumour you'd expect from the depths of Reddit — but brace yourself, because the truth is even more disturbing. Yes, illicit vapes being smuggled into Australia have been found laced with synthetic opioids, including protodesnitazene, a lab-made chemical that's up to 100 times stronger than morphine. These aren't just whispers — this was confirmed in both Australia and the UK in 2025. One puff of a contaminated vape? It could be your last. We're not talking metaphor here. We're talking respiratory arrest in minutes. You wouldn't accept a mystery pill from a stranger, but vapes from dodgy imports? Same danger, prettier packaging. Let's break down what you're actually inhaling You were built for clarity, stamina, freedom — not breathing a chemical cocktail. Every puff of a vape is like pouring gravel into the engine of your body — your lungs, your heart, your brain. Here's what's commonly hiding inside: • Nicotine – often more concentrated than cigarettes, and it hits your brain within seconds • Flavouring agents – including diacetyl, which causes 'popcorn lung' (a permanent lung disease) • Solvents – which turn into formaldehyde and acrolein when heated • Heavy metals – from the heating coil: lead, tin, nickel • And now: synthetic opioids – which can kill you before you even realise something's wrong. These chemicals aren't listed. These devices aren't tested like medication. You're breathing blindfolded. Why vaping is far more dangerous than you think The design of modern vape devices is one part science, one part sinister. They're engineered for maximum addiction speed — delivering a powerful nicotine hit faster than cigarettes. The younger you are, the worse the effect: vaping rewires your brain's reward system and primes you for lifelong substance addiction. Even without synthetic opioids, vaping can: • Reduce your oxygen capacity by 15–20 per cent in just one to two years • Cause irreversible lung damage • Shrink your VOâ‚‚ max — the oxygen your body uses during exercise • Leave you breathless walking up stairs at 25 Some young Aussies are presenting to clinics with the lungs of a 65-year-old smoker — after only a few years of vaping. That's not shock value. That's medical fact. And it's not just your lungs Vaping doesn't stop at damaging your lungs. It quietly targets your entire body: • Heart: raises blood pressure, hardens arteries, increases heart failure risk by 19 per cent • Brain: reshapes dopamine pathways, heightens risk of future drug use • DNA: causes cell mutations, accelerates ageing, and suppresses immunity The chemical mix also weakens your lungs' defences, making you more prone to pneumonia, bronchitis, and even severe Covid complications. You might feel fine now — but like asbestos and leaded petrol, vaping's true toll hits years after it's too late to undo the damage. So Rory … government scare campaign? Here's the honest truth: Governments aren't always perfect messengers — but illegal vapes are a proven threat. Not just because they're unregulated, but because of what's now being found in them. This isn't a PSA to push you into a clinic. It's a medical warning: You don't have to die from vaping to lose everything. You just have to keep doing it. So if you vape, now is the time to stop. If you haven't started, don't. And if someone offers you a colourful, fruit-scented stick from an unlabelled box? Politely say, 'I'm not ready to die for mango ice.' Breathe easy, Dr Zac. Got a question? Email askdrzac@ Dr Zac Turner is a medical practitioner specialising in preventative health and wellness. He has four health/medical degrees – Bachelor of Medicine/Bachelor of Surgery at the University of Sydney, Bachelor of Nursing at Central Queensland University, and Bachelor of Biomedical Science at the University of the Sunshine Coast. He is a registrar for the Australian College of Rural and Remote Medicine, and is completing a PhD in Biomedical Engineering (UNSW). Dr Zac is the medical director for his own holistic wellness medical clinics throughout Australia, Concierge Doctors.
